Table 2

Comparison of characteristics of patients with and without new vertebral fractures
Variables Patients without new VFs Patients with new VFs P-value
Mean ± SD or number (%) (n = 272) (n = 26)
Male 215 (79) 22 (85) 0.617
Age, years 33.8 ± 10.9 35.2 ± 12.2 0.526
Age at diagnosis, years 30.0 ± 10.6 31.6 ± 11.9 0.459
Disease duration, years 3.8 ± 5.1 3.6 ± 5.2 0.847
Family history of AS 24 (9) 3 (12) 0.717
HLA-B27-positive1 226 (93) 18 (82) 0.083
Back pain 267 (98.5) 26 (100) 1.000
History of peripheral arthritis 176 (65) 14 (54) 0.290
History of enthesitis 62 (23) 9 (35) 0.226
History of uveitis 85 (32) 2 (8) 0.012
Presence of baseline VF 22 (8) 9 (35) <0.001
Baseline BASDAI score 5.5 ± 1.8 5.2 ± 1.7 0.726
Baseline mean sacroiliitis grade 3.1 ± 0.7 3.1 ± 0.9 0.945
Baseline SASSS score 15.8 ± 1.0 13.1 ± 17.8 0.138
Significant SASSS progression2 47 (18) 9 (39) 0.026
Baseline ESR, mm/h 26.2 ± 1.6 24.4 ± 20.6 0.397
Baseline CRP, mg/L 1.8 ± 3.2 1.0 ± 1.3 0.251
Increase in ESR at 2 years 153 (56) 12 (46) 0.542
Increase in CRP at 2 years 50 (22) 9 (47) 0.020
Patients on NSAIDs 223 (82) 22 (85) 1.000
Patients on sulfasalazine 124 (46) 12 (46) 1.000
Patients on MTX 82 (30) 4 (15) 0.119
Patients on TNF inhibitors 112 (41) 6 (23) 0.093
Patients on calcium 31 (12) 2 (8) 0.751
Patients on bisphosphonate 8 (3) 0 (0) 0.475

1Confirmed in 265 patients; 2change ≥2 SASSS units over the first 2 years post-baseline. VF, vertebral fracture; AS, ankylosing spondylitis; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; BASDAI, Bath AS disease activity index; SASSS, Stokes ankylosing spondylitis spine score; NSAIDs, Non-steroidal anti-inflammatory drugs; MTX, Methotrexate; TNF, tumor necrosis factor.

Kang et al.

Kang et al. Arthritis Research & Therapy 2014 16:R124   doi:10.1186/ar4581

Open Data